Valeant (VRX) August weekly volatility elevated as shares up in premarket on Q2 and outlook

August 9, 2016 6:20 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Valeant Pharma (NYSE: VRX) is recently up $1.55 to $24 in the premarket on backs FY16 revenue guidance of $9.9B-$10.1B, compared to consensus $10.01B. August weekly call option implied volatility is at 147, August is at 109, September is at 84; compared to its 52-week range of 34 to 175.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment